Subacute toxicities and toxicokinetics of DA-8159, a new phosphodiesterase type V inhibitor, after single and 4-week repeated oral administration in rats

Biopharmaceutics and Drug Disposition

Volumn 24, Issue 9, 2003, Pages 409-418

  Shim, Hyun J ^a,b   Kim, Yu C ^a   Jang, Ji M ^b   Park, Kyung J ^b   Kim, Dong H ^b   Kang, Kyung K ^b   Ahn, Byoung O ^b   Kwon, Jong W ^b   Kim, Won B ^b   Lee, Myung G ^a  

^a Seoul National University   (South Korea)

^b Dong A Pharmaceutical Company   (South Korea)

Author keywords

DA 8159; Rats; Single and 4 week oral administration; Subacute toxicities; Toxicokinetics

Indexed keywords

DA 8164; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; UDENAFIL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILE DUCT DISEASE; BIOACCUMULATION; BLEEDING DISORDER; BLOOD CELL; BONE DENSITY; BONE MARROW; CELL INFILTRATION; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG RETENTION; DRUG STRUCTURE; ERYTHROCYTE; FEMALE; FIBROSIS; HEMATOLOGICAL PARAMETERS; HEMATOPOIESIS; INFLAMMATORY CELL; LACRIMAL GLAND DISEASE; LEUKOCYTE COUNT; LIVER WEIGHT; LOCOMOTION; LUNG ALVEOLUS MACROPHAGE; LUNG INFILTRATE; LUNG WEIGHT; MALE; MICROSCOPY; MOTOR DYSFUNCTION; NONHUMAN; PTOSIS; RAT; SPLEEN WEIGHT; TOXICITY TESTING; TOXICOKINETICS; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BODY WEIGHT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG ADMINISTRATION SCHEDULE; FEMALE; MALE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; ORGAN SIZE; PHOSPHODIESTERASE INHIBITORS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 9144227432     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.377     Document Type: Article

References (8)

1. Goldenberg MM. Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction. Clin Ther 1998; 20: 1033-1048.
2. Shim HJ, Lee EJ, Jung YH, et al. Determination of a new phosphodiesterase V inhibitor, DA-8159, in plasma and urine by high-performance liquid chromatography. J Pharm Biomed Anal 2002; 30: 527-533.
3. Shim HJ, Lee EJ, Kim SH, et al. Pharmacokinetics, stability and blood partition of DA-8159, a new phosphodiesterase V inhibitor. Res Commun Mol Pathol Pharmacol 2000; 108: 275-286.
4. Shim HJ, Lee EJ, Kim SH, et al. Factors influencing the protein binding of a new phosphodiesterase V inhibitor, DA-8159, using an equilibrium dialysis technique. Biopharm Drug Dispos 2000; 21: 285-291.
5. Shim HJ, Lee EJ, Kim SH, et al. Subacute toxicities and toxicokinetics of a new erectogenic, DA-8159, after single and 4-week repeated oral administration to dogs. Biopharm Drug Dispos 2001; 22: 109-117.
6. Shim HJ, Kim YC, Park KJ, et al. Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: Hepatic and intestinal first-pass effects. J Pharm Sci 2003 (in press)
7. Viagra® Product Information. Pfizer Inc. NDA 20-895. 1988.
8. Chiou WL. Critical evaluation of the potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokin Biopharm 1978; 6: 539-546.